GNPX

Genprex, Inc. NASDAQ Listed Mar 29, 2018

Healthcare ·Biotechnology ·US · genprex.com

$0.83

-3.60% vs $0.86

Mkt Cap $1.4M

52w Low $0.81 0.0% of range 52w High $55.00

50d MA $1.41 200d MA $5.17

P/E (TTM) -0.1x

EV/EBITDA —

P/B 0.1x

Debt/Equity 0.0x

ROE -203.8%

P/FCF -0.1x

RSI (14) —

ATR (14) —

Beta -0.67

50d MA $1.41

200d MA $5.17

Avg Volume 988.1K

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

SIC Code

2834

CIK (SEC)

1595248

Phone

877 774 4679

3300 Bee Cave Road · Austin, TX 78746 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 30, 2026	AMC	-13.00	-1.15	+91.2%	1.77	-2.3%	+2.3%	-12.7%	-2.5%	-5.8%	-5.5%	—
Nov 14, 2025	AMC	-12.50	-5.00	+60.0%	4.43	+0.0%	-8.8%	-8.7%	-9.5%	-5.4%	-5.1%	—
Aug 14, 2025	AMC	-21.00	-8.50	+59.5%	10.80	+0.1%	-1.8%	-10.0%	-10.9%	-4.2%	-11.8%	—
May 12, 2025	AMC	-0.82	-0.26	+68.3%	13.80	+1.5%	+2.2%	-20.9%	+6.2%	+4.4%	+9.2%	—
Apr 7, 2025	AMC	-0.82	-1.15	-40.2%	15.51	+4.8%	-17.9%	+8.0%	-3.6%	+0.6%	-0.8%	—
Nov 13, 2024	AMC	-1.13	-1.23	-8.8%	80.00	+2.5%	+2.5%	-2.4%	-15.0%	-5.1%	-14.7%	—
Aug 9, 2024	AMC	-2.30	-3.00	-30.4%	71.00	+4.9%	-11.3%	-32.5%	-14.1%	-10.7%	-0.6%	—
May 15, 2024	AMC	-2.54	-3.69	-45.3%	125.50	-1.2%	-3.6%	+5.4%	-4.3%	-3.7%	+0.9%	—
Mar 29, 2024	AMC	-3.93	-3.96	-0.8%	—	—	—	—	—	—	—	—
Nov 14, 2023	AMC	-0.11	-5.20	-4627.3%	470.00	+1.5%	+10.6%	-8.4%	+3.9%	+4.8%	-0.7%	—
Aug 21, 2023	AMC	-4.80	-6.00	-25.0%	898.50	-2.6%	+7.8%	-5.2%	-0.3%	+1.6%	+0.4%	—
May 22, 2023	AMC	-4.80	-7.60	-58.3%	1575.00	-0.3%	-0.2%	-0.8%	+9.0%	+4.7%	-9.7%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$121.00	$124.50	+2.9%	+5.4%	-4.3%	-3.7%	+0.9%	-6.8%
May 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$128.50	$127.00	-1.2%	-2.3%	-3.6%	+5.4%	-4.3%	-3.7%
Apr 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$155.50	$157.50	+1.3%	-3.9%	+0.3%	-1.3%	+3.7%	-6.2%
Apr 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$142.00	$144.50	+1.8%	+9.5%	-3.9%	+0.3%	-1.3%	+3.7%

Data updated apr 25, 2026 11:52am · Source: massive.com